These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 1813880)

  • 1. [Late results of the treatment of advanced Hodgkin's disease by the MOPP/COPP programs (chlormethine or cyclophosphamide, vincristine, procarbazine and prednisone)].
    Błasińska-Morawiec M; Płuzańska A; Krykowski E; Robak T; Mrówka I
    Pol Arch Med Wewn; 1991 Oct; 86(4):274-80. PubMed ID: 1813880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Chemotherapy of advanced lymphogranulomatosis. Results of MOPP/COPP treatment at the West German Tumor Center, Essen].
    Höffken K; Ippisch A; Pfeiffer R; Becher R; Seeber S; Schmidt CG
    Dtsch Med Wochenschr; 1985 Apr; 110(16):618-23. PubMed ID: 3838719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can MOPP be replaced in the treatment of advanced Hodgkin's disease?
    Canellos GP
    Semin Oncol; 1990 Feb; 17(1 Suppl 2):2-6. PubMed ID: 1689509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
    Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prognostic value of the results of short-term polychemotherapy by the MOPP program of Hodgkin's disease stages III and IV].
    Hansz J; Burchardt K; Komarnicki M; Trepińska E; Psuja P
    Pol Arch Med Wewn; 1984 Dec; 72(6):293-8. PubMed ID: 6549512
    [No Abstract]   [Full Text] [Related]  

  • 6. Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin's disease: seven-year results of a prospective randomized trial.
    Longo DL; Glatstein E; Duffey PL; Young RC; Hubbard SM; Urba WJ; Wesley MN; Raubitschek A; Jaffe ES; Wiernik PH
    J Clin Oncol; 1991 Jun; 9(6):906-17. PubMed ID: 2033427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group.
    Pfreundschuh MG; Schoppe WD; Fuchs R; Pflüger KH; Loeffler M; Diehl V
    Cancer Treat Rep; 1987 Dec; 71(12):1203-7. PubMed ID: 2446751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of advanced-stage massive mediastinal Hodgkin's disease: the case for combined modality treatment.
    Longo DL; Russo A; Duffey PL; Hubbard SM; Glatstein E; Hill JB; Jaffe ES; Young RC; DeVita VT
    J Clin Oncol; 1991 Feb; 9(2):227-35. PubMed ID: 1988570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study.
    Bakemeier RF; Anderson JR; Costello W; Rosner G; Horton J; Glick JH; Hines JD; Berard CW; DeVita VT
    Ann Intern Med; 1984 Oct; 101(4):447-56. PubMed ID: 6089632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized study for the treatment of advanced Hodgkin's disease: MOPP vs. LOPP.
    Avilés A; Díaz-Maqueo JC; García EL; Torras V; López-Vancell D
    Arch Invest Med (Mex); 1991; 22(1):45-50. PubMed ID: 1819976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of pediatric Hodgkin's disease with chemotherapy alone or combined modality therapy.
    Muwakkit S; Geara F; Nabbout B; Farah RA; Shabb NS; Hajjar T; Khogali M
    Radiat Oncol Investig; 1999; 7(6):365-73. PubMed ID: 10644060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [CVP or C-MOPP combination chemotherapy in the treatment of advanced Hodgkin's disease and non-Hodgkin's lymphoma (intermediate grade of working formulation)].
    Sampi K; Honda T; Hattori M
    Rinsho Ketsueki; 1984 Feb; 25(2):164-8. PubMed ID: 6547984
    [No Abstract]   [Full Text] [Related]  

  • 13. Free-from-failure survival in Hodgkin's disease. Long-term analysis of 148 cases treated with a MOPP-modified protocol.
    Silingardi V; Federico M; Frassoldati A; Barbieri F; Palomba G; Mauri C
    Acta Haematol; 1989; 82(4):179-86. PubMed ID: 2511719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group.
    Connors JM; Klimo P; Adams G; Burns BF; Cooper I; Meyer RM; O'Reilly SE; Pater J; Quirt I; Sadura A; Shustik C; Skillings J; Sutcliffe S; Verma S; Yoshida S; Zee B
    J Clin Oncol; 1997 Apr; 15(4):1638-45. PubMed ID: 9193364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of advanced Hodgkin's disease with modified MOPP regimens. A long-term observation.
    Koza I; Bohunický L; Svancárová L; Mardiak J; Gyárfás J; Cerný V
    Neoplasma; 1989; 36(6):709-18. PubMed ID: 2615874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.
    Diehl V; Franklin J; Hasenclever D; Tesch H; Pfreundschuh M; Lathan B; Paulus U; Sieber M; Rueffer JU; Sextro M; Engert A; Wolf J; Hermann R; Holmer L; Stappert-Jahn U; Winnerlein-Trump E; Wulf G; Krause S; Glunz A; von Kalle K; Bischoff H; Haedicke C; Duehmke E; Georgii A; Loeffler M
    J Clin Oncol; 1998 Dec; 16(12):3810-21. PubMed ID: 9850026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of advanced-stage Hodgkin's disease: alternating noncrossresistant MOPP/CABS is not superior to MOPP.
    Longo DL; Duffey PL; DeVita VT; Wiernik PH; Hubbard SM; Phares JC; Bastian AW; Jaffe ES; Young RC
    J Clin Oncol; 1991 Aug; 9(8):1409-20. PubMed ID: 1712836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized study for the treatment of adult advanced Hodgkin's disease: mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) versus lomustine, vinblastine, and prednisone.
    Liebman HA; Hum GJ; Sheehan WW; Ryden VM; Bateman JR
    Cancer Treat Rep; 1983 May; 67(5):413-9. PubMed ID: 6342771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mopp chemotherapy in the treatment of stage IV Hodgkin's disease.
    Fiacchini M; Lauria F; Mazza P; Cantore M; Gherlinzoni F; Tura S
    Haematologica; 1985; 70(2):148-54. PubMed ID: 3924778
    [No Abstract]   [Full Text] [Related]  

  • 20. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.
    Diehl V; Franklin J; Pfreundschuh M; Lathan B; Paulus U; Hasenclever D; Tesch H; Herrmann R; Dörken B; Müller-Hermelink HK; Dühmke E; Loeffler M;
    N Engl J Med; 2003 Jun; 348(24):2386-95. PubMed ID: 12802024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.